Industry Verticals »

All Categories

Insights »

About TMR »

Unfractionated Heparin Market

Unfractionated Heparin Market (Source -Bovine and Porcine; Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies) - Global Industry Analysis, Size, Share, Growth, Trends, & Forecast 2019- 2027

Unfractionated Heparin Market: Snapshot

The global unfractionated heparin market is set to collect handsome revenues during the forecast period of 2019 to 2027. This growth is attributed to a plethora of factors. Unfractionated heparin is a naturally occurring anticoagulant. Owing to its ability to prevent blood clots, unfractionated heparin is widely used in heart lungs, and dialysis machines. At the same time, it is effective for treating blood clotting disorders such as pulmonary embolism and deep venous thrombosis. All these applications suggest that the global unfractionated heparin market will witness stupendous demand avenues in the forthcoming years.

Unfractionated heparin is gaining traction owing to the plethora of features it holds. It is widely accepted due to its instantaneous onset of action, uncomplicated laboratory monitoring, short half-life, and ability to get reversed (protamine). Apart from this, it is cost-efficient. Unfractionated heparin is also used for treating venous thromboembolism (VTE) including pulmonary embolism (PE) and deep vein thrombosis (DVT). This factor is stimulating the growth of the global unfractionated heparin industry.

In recent years, there is a considerable increase in the number of surgical procedures. This factor is working as a driver for the global unfractionated heparin market. Vendors working in the market for unfractionated heparin hold phenomenal avenues for growth during forthcoming years. One of the key reasons for this growth is the patent expiration for major unfractionated heparin.

On the regional front, the unfractionated heparin market is expected to gain lucrative avenues in Europe. A key reason for this growth is considerable growth in the number of research activities and increased cases of diseases in the region. In addition to this, the market for unfractionated heparin is expected to grow at a swift speed in Asia Pacific. Key factors supporting the growth of the unfractionated heparin market are an increase in the older population, an improved initiative by government bodies to advance the healthcare sector, and the presence of major players in the region.

  • This report analyzes the current scenario and future prospects of the global unfractionated heparin market. Unfractionated heparin is a naturally occurring anticoagulant that is primarily in dialysis and heart-lung machines to prevent blood clots as well as for the treatment of blood clotting disorders like deep venous thrombosis and pulmonary embolism. Its immediate onset of action, short half-life, simple laboratory monitoring, ability to get reversed (protamine), and low cost have led to its wide adoption.
  • An increase in the use of unfractionated heparin for the treatment of venous thromboembolism (VTE) including deep vein thrombosis (DVT) and pulmonary embolism (PE) along with an increasing number of surgical procedures are the major drivers for the global market for unfractionated heparin. Although unfractionated heparin is one of the most primitive forms of heparin, the narrow therapeutic window and risk associated with bleeding act as the major restraints to its market across the globe.
  • Patent expiration for the majority of unfractionated heparin has already created a huge latent opportunity for generic and biosimilar manufacturers in the forthcoming years. This will have a positive impact on the market.
  • According to the World Health Organization (WHO), prolonged traveling by passengers via any automobile, train, or airplane for more than four hours increases the risk of developing venous thromboembolism. Coagulation disorders such as venous thromboembolism (VTE), which includes both deep vein thrombosis and pulmonary embolism, affect approximately 1 million people in the U.S. every year. According to the Centers for Disease Control and Prevention, approximately 500,000 to 900,000 people in the U.S. are affected by VTE every year. A study published by Deutsches Arzteblatt International in 2013 revealed that the annual incidence rate of diagnosed VTE in Germany stood at 150 to 200 cases per 100,000. The statistics above clearly indicate the demand for safe, reliable, and affordable anticoagulants. Simultaneously it is expected to drive the global unfractionated heparin market.
  • The report provides an elaborate executive summary, which includes a snapshot of various segments of the global unfractionated heparin business. It also provides information and data analysis of the global market for unfractionated heparin with regards to segments based on source and distribution channel, and region.
  • The overview section of the unfractionated heparin market report provides a detailed qualitative analysis of drivers, restraints, and opportunities that impact the global unfractionated heparin business
  • The report includes company profiles that provide information about their business, product portfolios, and competitive landscape in the global unfractionated heparin industry
  • The report on the global market for unfractionated heparin also offers a market attractiveness analysis of regions and segments
  • The last section of the global unfractionated heparin market report comprises quantitative and qualitative analysis of the market share/position of key players operating in the global unfractionated heparin industry. It analyzes key competitive strategies adopted by major industry players, thereby presenting a thorough understanding of the competitive scenario in the global market for unfractionated heparin.
  • The market size of the global unfractionated heparin and forecast for each of the segments have been provided from 2017 to 2027. The CAGRs of respective segments have also been provided from 2019 to 2027, considering 2018 as the base year.

Global: Regional Outlook

  • In terms of region, the global unfractionated heparin market has been segmented into North America (the U.S. and Canada), Europe (the U.K., Germany, Spain, Italy, France, and the Rest of Europe), Asia Pacific (China, India, Japan, Australia & New Zealand, and Rest of Asia Pacific), Latin America (Brazil, Mexico, and Rest of Latin America), and Middle East & Africa (GCC Countries, South Africa, Israel, and Rest of Middle East & Africa). Each region considered in the market has been further divided into countries/sub-regions.
  • The unfractionated heparin industry report provides size and forecast for each region and country/sub-region from 2017 to 2027. The CAGR for each of these regions and countries has also been provided for the forecast period from 2019 to 2027. The global market for unfractionated heparin study also covers the competitive scenario in these regions.

Companies Covered in Global Unfractionated heparin market Report

  • Key players in the global market for unfractionated heparin have been profiled based on attributes such as company overview, product portfolio, financial overview, recent developments, and competitive business strategies.
  • Major players having a presence in the global unfractionated heparin business include
    • Becton
    • Dickinson and Company
    • bioMérieux S.A.
    • Bio-Rad Laboratories, Inc
    • Eiken Chemical Co, Ltd.
    • EMD (Merck) Millipore
    • Hi-Media Laboratories Pvt. Ltd.
    • Neogen Corporation
    • Sigma-Aldrich Co. LLC
    • Scharlab S.L.
    • Thermo Fisher Scientific,

Global Unfractionated Heparin Market - Segmentation

Source

Bovine

Porcine

Distribution Channel

Hospital Pharmacies

Retail Pharmacies

Online Pharmacies

Region

North America

Europe

Asia Pacific

Latin America

Middle East & Africa

Frequently Asked Questions

What is the total market worth of unfractionated heparin?

Unfractionated heparin market to reach US$ 1.7 Bn by 2027

What is the anticipated CAGR of the global market for unfractionated heparin in the forecast period?

The global market is to expand at a CAGR of 6.4% from 2019 to 2027

What are the key driving factors for the growth of the global market for unfractionated heparin?

The global market is driven by an increasing number of surgical procedures

Which region is expected to project the highest market share in the global unfractionated heparin?

Asia Pacific is expected to account for highest market share during the forecast period

Who are the key players in the unfractionated heparin business?

Key players in the global unfractionated heparin industry include Becton, Dickinson and Company, bioMérieux S.A., Bio-Rad Laboratories, Inc, Eiken Chemical Co, Ltd.

    1. Preface

         1.1. Report Scope and Market Segmentation

         1.2. Research Highlights

    2. Assumptions and Research Methodology

         2.1. Assumptions

         2.2. Research Methodology

         2.3. Acronyms Used

    3. Executive Summary

    4. Market Overview

         4.1. Product Overview

         4.2. Drivers and Restraints Snapshot Analysis

         4.3. Drivers

             4.3.1. Rise in the incidence of coagulation and renal and heart diseases

             4.3.2. Inclination of slaughterhouse owners toward entering into the crude unfractionated heparin processing business

             4.3.3. Ban on imports from China to boost production in Europe

         4.4. Restraints

             4.4.1. Availability of alternative anticoagulants

             4.4.2. Enhanced quality control measures

             4.4.3. Patent expiry and increasing use of off-label products

         4.5. Opportunities

             4.5.1. Biosimilar-based heparin products

             4.5.2. Heparin diversification: alternative sources of unfractionated heparin

         4.6. Key Trends

         4.7. Opportunity Analysis

         4.8. Global Unfractionated Heparin Market Size (US$ Mn) Forecast

    5. Global Unfractionated Heparin Market Analysis, by Source

         5.1. Key Findings

         5.2. Introduction

         5.3. Global Unfractionated Heparin Market Value Share Analysis, by Source

         5.4. Global Unfractionated Heparin Market Forecast, by Source

             5.4.1. Bovine 

             5.4.2. Porcine

         5.5. Global Unfractionated Heparin Market Analysis, by Source

         5.6. Global Unfractionated Heparin Market Attractiveness Analysis, by Source

    6. Global Unfractionated Heparin Market Analysis, by Distribution Channel

         6.1. Key Findings

         6.2. Introduction

         6.3. Global Unfractionated Heparin Market Value Share Analysis, by Distribution Channel

         6.4. Global Unfractionated Heparin Market Forecast, by Distribution Channel

             6.4.1. Hospital Pharmacies

             6.4.2. Retail Pharmacies

             6.4.3. Online Pharmacies

         6.5. Global Unfractionated Heparin Market Analysis, by Distribution Channel

         6.6. Global Unfractionated Heparin Market Attractiveness Analysis, by Distribution Channel

    7. Global Unfractionated Heparin Market Analysis, by Region

         7.1. Global Unfractionated Heparin Market Scenario, by Country

         7.2. Global Unfractionated Heparin Market Value Share Analysis, by Region

         7.3. Global Unfractionated Heparin Market Forecast, by Region

             7.3.1. North America

             7.3.2. Europe

             7.3.3. Asia Pacific

             7.3.4. Latin America

             7.3.5. Middle East and Africa

         7.4. Global Unfractionated Heparin Market Attractiveness Analysis, by Region

    8. North America Unfractionated Heparin Market Analysis

         8.1. Key Findings

         8.2. North America Unfractionated Heparin Market Overview

         8.3. North America Unfractionated Heparin Market Value Share Analysis, by Source

         8.4. North America Unfractionated Heparin Market Forecast, by Source

         8.5. North America Unfractionated Heparin Market Value Share Analysis, by Distribution Channel

         8.6. North America Unfractionated Heparin Market Forecast, by Distribution Channel

         8.7. North America Unfractionated Heparin Market Attractiveness Analysis 

         8.8. North America Unfractionated Heparin Market Value Share Analysis, by Country

             8.8.1. U.S.

             8.8.2. Canada

    9. Europe Unfractionated Heparin Market Analysis

         9.1. Key Findings

         9.2. Europe Unfractionated Heparin Market Overview

         9.3. Europe Unfractionated Heparin Market Value Share Analysis, by Source

         9.4. Europe Unfractionated Heparin Market Forecast, by Source

         9.5. Europe Unfractionated Heparin Market Value Share Analysis, by Distribution Channel

         9.6. Europe Unfractionated Heparin Market Forecast, by Distribution Channel

         9.7. Europe Unfractionated Heparin Market Attractiveness Analysis 

         9.8.  Europe Unfractionated Heparin Market Value Share Analysis, by Country

         9.9. Europe Unfractionated Heparin Market Forecast, by Country

             9.9.1. Germany 

             9.9.2. U.K.

             9.9.3. France

             9.9.4. Italy

             9.9.5. Spain

             9.9.6. Rest of the Europe 

    10. Asia Pacific Unfractionated Heparin Market Analysis

         10.1. Key Findings

         10.2. Asia Pacific Unfractionated Heparin Market Overview

         10.3. Asia Pacific Unfractionated Heparin Market Value Share Analysis, by Source

         10.4. Asia Pacific Unfractionated Heparin Market Forecast, by Source

         10.5. Asia Pacific Unfractionated Heparin Market Value Share Analysis, by Distribution Channel

         10.6. Asia Pacific Unfractionated Heparin Market Forecast, by Distribution Channel

         10.7. Asia Pacific Unfractionated Heparin Market Attractiveness Analysis 

         10.8. Asia Pacific Unfractionated Heparin Market Value Share Analysis, by Country

         10.9. Asia Pacific Unfractionated Heparin Market Forecast, by Country

             10.9.1. China

             10.9.2. India

             10.9.3. Japan

             10.9.4. Australia 

             10.9.5. Indonesia

             10.9.6. Malaysia

             10.9.7. Rest of Asia Pacific

    11. Latin America Unfractionated Heparin Market Analysis

         11.1. Key Findings

         11.2. Latin America Unfractionated Heparin Market Overview

         11.3. Latin America Unfractionated Heparin Market Value Share Analysis, by Source

         11.4. Latin America Unfractionated Heparin Market Forecast, by Source

         11.5. Latin America Unfractionated Heparin Market Value Share Analysis, by Distribution Channel

         11.6. Latin America Unfractionated Heparin Market Forecast, by Distribution Channel

         11.7. Latin America Unfractionated Heparin Market Attractiveness Analysis 

         11.8. Latin America Unfractionated Heparin Market Value Share Analysis, by Country

         11.9. Latin America Unfractionated Heparin Market Forecast, by Country

             11.9.1. Brazil

             11.9.2. Mexico 

             11.9.3. Rest of LATAM 

    12.  Middle East & Africa Unfractionated Heparin Market Analysis

         12.1. Key Findings

         12.2. Middle East & Africa Unfractionated Heparin Market Overview

         12.3. Middle East & Africa Unfractionated Heparin Market Value Share Analysis, by Source

         12.4. Middle East & Africa Unfractionated Heparin Market Forecast, by Source

         12.5. Middle East & Africa Unfractionated Heparin Market Value Share Analysis, by Distribution Channel

         12.6. Middle East & Africa Unfractionated Heparin Market Forecast, by Distribution Channel

         12.7. Middle East & Africa Unfractionated Heparin Market Attractiveness Analysis 

         12.8. Middle East & Africa Unfractionated Heparin Market Value Share Analysis, by Country

         12.9. Middle East & Africa Unfractionated Heparin Market Forecast, by Country

             12.9.1. GCC Countries

             12.9.2. South Africa

             12.9.3. Israel

             12.9.4. Rest of Middle East & Africa

    13. Competition Landscape

         13.1. Market Share Analysis

         13.2. Competition Matrix

             13.2.1. Fresenius SE & Co. KGaA 

                 13.2.1.1. Company Details

                 13.2.1.2. Business Overview

                 13.2.1.3. Financial Overview

                 13.2.1.4. Strategic Overview

                 13.2.1.5. SWOT Analysis

             13.2.2. Pfizer, Inc. 

                 13.2.2.1. Company Details

                 13.2.2.2. Business Overview

                 13.2.2.3. Financial Overview

                 13.2.2.4. Strategic Overview

                 13.2.2.5. SWOT Analysis

             13.2.3. LEO Pharma A/S 

                 13.2.3.1. Company Details

                 13.2.3.2. Business Overview

                 13.2.3.3. Financial Overview

                 13.2.3.4. Strategic Overview

                 13.2.3.5. SWOT Analysis

             13.2.4. Baxter International Inc. 

                 13.2.4.1. Company Details

                 13.2.4.2. Business Overview

                 13.2.4.3. Financial Overview

                 13.2.4.4. Strategic Overview

                 13.2.4.5. SWOT Analysis

             13.2.5. B. Braun Melsungen AG 

                 13.2.5.1. Company Details

                 13.2.5.2. Business Overview

                 13.2.5.3. Financial Overview

                 13.2.5.4. Strategic Overview

                 13.2.5.5. SWOT Analysis

             13.2.6. Sagent Pharmaceuticals, Inc. (Nichi-Iko Pharmaceutical Co.)

                 13.2.6.1. Company Details

                 13.2.6.2. Business Overview

                 13.2.6.3. Financial Overview

                 13.2.6.4. Strategic Overview

                 13.2.6.5. SWOT Analysis

             13.2.7. Mylan Inc. 

                 13.2.7.1. Company Details

                 13.2.7.2. Business Overview

                 13.2.7.3. Financial Overview

                 13.2.7.4. Strategic Overview

                 13.2.7.5. SWOT Analysis

             13.2.8. Other Prominent Players

    List of Tables

    Table 1: Global Unfractionated Heparin Market Value (US$ Mn) Forecast, by Source, 2017–2027

    Table 2: Global Unfractionated Heparin Market Value (US$ Mn) Forecast, by Distribution Channel, 2017–2027

    Table 3: Global Unfractionated Heparin Market Value (US$ Mn) Forecast, by Region, 2017–2027

    Table 4: North America Unfractionated Heparin Market Value (US$ Mn) Forecast, by Source, 2017–2027

    Table 5: North America Unfractionated Heparin Market Value (US$ Mn) Forecast, by Distribution Channel, 2017–2027

    Table 6: North America Unfractionated Heparin Market Value (US$ Mn) Forecast, by Country, 2017–2027

    Table 7: Europe Unfractionated Heparin Market Value (US$ Mn) Forecast, by Source, 2017–2027

    Table 8: Europe Unfractionated Heparin Market Value (US$ Mn) Forecast, by Distribution Channel, 2017–2027

    Table 9: Europe Unfractionated Heparin Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2027

    Table 10: Asia Pacific Unfractionated Heparin Market Value (US$ Mn) Forecast, by Source, 2017–2027

    Table 11: Asia Pacific Unfractionated Heparin Market Value (US$ Mn) Forecast, by Distribution Channel, 2017–2027

    Table 12: Asia Pacific Unfractionated Heparin Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2027

    Table 13: Latin America Unfractionated Heparin Market Value (US$ Mn) Forecast, by Source, 2017–2027

    Table 14: Latin America Unfractionated Heparin Market Value (US$ Mn) Forecast, by Distribution Channel, 2017–2027

    Table 15: Latin America Unfractionated Heparin Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2027

    Table 16: Middle East & Africa Unfractionated Heparin Market Value (US$ Mn) Forecast, by Source, 2017–2027

    Table 17: Middle East & Africa Unfractionated Heparin Market Value (US$ Mn) Forecast, by Distribution Channel, 2017–2027

    Table 18: Middle East & Africa Unfractionated Heparin Market Value (US$ Mn) Forecast, by Country, 2017–2027

    Table 19: Fresenius SE & Co. KGaA Products Offering

    Table 20: Pfizer, Inc. products offering

    Table 21: Leo Pharma A/S products offering

    Table 22: Baxter International Inc. Products Offering

    Table 23: B.Braun Melsungen AG Products Offering

    Table 24: Sagent Pharmaceuticals, Inc. Products Offering

    Table 25: Mylan Inc. Products Offering

    List of Figures

    Figure 01: Global Unfractionated Heparin Market Share (US$ Mn), by Distribution Channel, 2016

    Figure 02: Global Unfractionated Heparin Market Share (%), by Source, 2016

    Figure 03: Revenue Share, 2018

    Figure 04: Global Unfractionated Heparin Market Revenue (US$ Mn) Forecast and Y-o-Y Growth (%), 2019–2027

    Figure 05: Market Value Share, by Source (2018)

    Figure 06: Market Value Share, by Distribution Channel (2018)

    Figure 07: Market Value Share, by Region (2018) 

    Figure 08: Global Unfractionated Heparin Market Value Share Analysis, by Source, 2018 and 2027

    Figure 09: Global Unfractionated Heparin Market Revenue (US$ Mn) and Y-o-Y Growth (%), by Bovine, 2017–2027

    Figure 10: Global Unfractionated Heparin Market Revenue (US$ Mn) and Y-o-Y Growth (%), by Porcine, 2017–2027

    Figure 11: Global Unfractionated Heparin Market Attractiveness, by Source

    Figure 12: Global Unfractionated Heparin Market Value Share, by Distribution Channel, 2018 and 2027

    Figure 13: Global Unfractionated Heparin Market Revenue (US$ Mn) and Y-o-Y Growth (%), by Hospital Pharmacies, 2017–2027

    Figure 14: Global Unfractionated Heparin Market Revenue (US$ Mn) and Y-o-Y Growth (%), by Retail Pharmacies, 2017–2027

    Figure 15: Global Unfractionated Heparin Market Revenue (US$ Mn) and Y-o-Y Growth (%), by Online Pharmacies, 2017–2027

    Figure 16: Global Unfractionated Heparin Market Attractiveness, by Distribution Channel

    Figure 17: Global Unfractionated Heparin Market Value Share, by Region, 2018 and 2027

    Figure 18: Global Unfractionated Heparin Market Attractiveness, by Region

    Figure 19: North America Unfractionated Heparin Market Size (US$ Mn) Forecast, 2019–2027

    Figure 20: North America Unfractionated Heparin Market Attractiveness Analysis, by Country, 2019–2027

    Figure 21: North America Unfractionated Heparin Market Value Share Analysis, by Source, 2018 and 2027

    Figure 22: North America Unfractionated Heparin Market Value Share Analysis, by Distribution Channel, 2018 and 2027

    Figure 23: North America Unfractionated Heparin Market Attractiveness Analysis, by Source, 2019–2027

    Figure 24: North America Unfractionated Heparin Market Attractiveness Analysis, by Distribution Channel, 2019–2027

    Figure 25: North America Unfractionated Heparin Market Value Share Analysis, by Country, 2018 and 2027

    Figure 26: Europe Unfractionated Heparin Market Size (US$ Mn) Forecast, 2019–2027

    Figure 27: Europe Unfractionated Heparin Market Attractiveness Analysis, by Country/Sub-region

    Figure 28: Europe Unfractionated Heparin Market Value Share Analysis, by Source, 2018 and 2027

    Figure 29: Europe Unfractionated Heparin Market Value Share Analysis, by Distribution Channel, 2018 and 2027

    Figure 30: Europe Unfractionated Heparin Market Attractiveness Analysis, by Source

    Figure 31: Europe Unfractionated Heparin Market Attractiveness Analysis, by Distribution Channel

    Figure 32: Europe Unfractionated Heparin Market Value Share Analysis, by Country/Sub-region, 2018 and 2027

    Figure 33: Asia Pacific Unfractionated Heparin Market Size (US$ Mn) Forecast, 2019–2027

    Figure 34: Asia Pacific Unfractionated Heparin Market Attractiveness Analysis, by Country/Sub-region

    Figure 35: Asia Pacific Unfractionated Heparin Market Value Share Analysis, by Source, 2018 and 2027

    Figure 36: Asia Pacific Unfractionated Heparin Market Value Share Analysis, by Distribution Channel, 2018 and 2027

    Figure 37: Asia Pacific Unfractionated Heparin Market Attractiveness Analysis, by Source

    Figure 38: Asia Pacific Unfractionated Heparin Market Attractiveness Analysis, by Distribution Channel

    Figure 39: Asia Pacific Unfractionated Heparin Market Value Share Analysis, by Country/Sub-region, 2018 and 2027

    Figure 40: Latin America Unfractionated Heparin Market Size (US$ Mn) Forecast, 2019–2027

    Figure 41: Latin America Unfractionated Heparin Market Attractiveness Analysis, by Country/Sub-region

    Figure 42: Latin America Unfractionated Heparin Market Value Share Analysis, by Source, 2018 and 2027

    Figure 43: Latin America Unfractionated Heparin Market Value Share Analysis, by Distribution Channel, 2018 and 2027

    Figure 44: Latin America Unfractionated Heparin Market Attractiveness Analysis, by Source

    Figure 45: Latin America Unfractionated Heparin Market Attractiveness Analysis, by Distribution Channel

    Figure 46: Latin America Unfractionated Heparin Market Value Share Analysis, by Country/Sub-region, 2018 and 2027

    Figure 47: Middle East & Africa Unfractionated Heparin Market Size (US$ Mn) Forecast, 2019–2027

    Figure 48: Middle East & Africa Unfractionated Heparin Market Attractiveness Analysis, by Country

    Figure 49: Middle East & Africa Unfractionated Heparin Market Value Share Analysis, by Source, 2018 and 2027

    Figure 50: Middle East & Africa Unfractionated Heparin Market Value Share Analysis, by Distribution Channel, 2018 and 2027

    Figure 51: Middle East & Africa Unfractionated Heparin Market Attractiveness Analysis, by Source

    Figure 52: Middle East & Africa Unfractionated Heparin Market Attractiveness Analysis, by Distribution Channel

    Figure 53: Middle East & Africa Unfractionated Heparin Market Value Share Analysis, by Country, 2018 and 2027

    Figure 54: Fresenius SE & Co. KGaA Revenue (US$ Mn) & Y-o-Y Growth (%), 2013–2016

    Figure 55: Fresenius SE & Co. KGaA R&D Intensity and Sales & Marketing Intensity (%) – Company Level, 2015–2016

    Figure 56: Fresenius SE & Co. KGaA Breakdown of Net Sales, By Region 2016

    Figure 57: Fresenius SE & Co. KGaA Breakdown of Net Sales, by Segment, (overall company level), 2016

    Figure 58: Pfizer, Inc. Revenue (US$ Mn) & Y-o-Y Growth (%), 2013–2016

    Figure 59: Pfizer, Inc. R&D Intensity and Sales & Marketing Intensity (%) – Company Level, 2015–2016

    Figure 60: Pfizer, Inc. Breakdown of Net Sales, By Region 2016

    Figure 61: Pfizer, Inc. Breakdown of Net Sales, By Business Segments, 2017

    Figure 62: LEO Pharma A/S Revenue (US$ Mn) & Y-o-Y Growth (%), 2013–2016

    Figure 63: LEO Pharma A/S Breakdown of Net Sales, By Region, 2017

    Figure 64: LEO Pharma A/S Breakdown of Net Sales, By Business Segments, 2017

    Figure 65: Baxter International Inc. Revenue (US$ Mn) & Y-o-Y Growth (%), 2013–2016

    Figure 66: Baxter International Inc. R&D Intensity and Sales & Marketing Intensity (%) – Company Level, 2015–2016

    Figure 67: Baxter International Inc. Breakdown of Net Sales, By Region 2016

    Figure 68: Baxter International Inc. Breakdown of Net Sales, (Overall Company Level), 2016

    Figure 69: B. Braun Melsungen AG Revenue (US$ Mn) & Y-o-Y Growth (%), 2013–2016

    Figure 70: B. Braun Melsungen AG R&D Intensity and Sales & Marketing Intensity (%) – Company Level, 2015–2016

    Figure 71: B. Braun Melsungen AG Breakdown of Net Sales, By Region 2016

    Figure 72: B. Braun Melsungen AG Breakdown of Net Sales, (Overall Company Level), 2016

    Figure 73: Mylan Inc. Revenue (US$ Mn) & Y-o-Y Growth (%), 2013–2016

    Figure 74: Mylan Inc. R&D Intensity and Sales & Marketing Intensity (%) 2014–2016

    Figure 75: Mylan Inc. Breakdown of Net Sales, By Region, 2016

Copyright © Transparency Market Research, Inc. All Rights reserved

Unfractionated Heparin Market

Schedule a Call